Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Breast 2Sarcoma 1

Conditions

Uveal Melanoma 2Melanoma 2Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Specimen Handling 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
CR011-vcMMAE × Dermatologic × Clear all
NCT02363283 2020-08-21

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT00412828 2015-02-19

A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma

Celldex Therapeutics

Phase 1/2 Completed
117 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡